Therapeutic Plasma Exchange Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

The Therapeutic Plasma Exchange Market was valued at USD 1.64 Billion in 2024, and is expected to reach USD 2.57 Billion by 2030, rising at a CAGR of 7.77%. Therapeutic plasma exchange (TPE), also known as plasmapheresis, is an endovascular blood technique utilized to separate pathogenic substances from clients' blood and replace them with replacement fluid, such as albumin solution or fresh frozen plasma. These substances encompass infective autoantibodies, immune complexes, cryoglobulins, and cholesterol-containing lipoproteins.

TPE is employed in the treatment of various autoimmune conditions, renal disorders, hematological disorders, and more, contributing to market expansion. Additionally, therapeutic plasma exchange (TPE) offers the significant benefit of reducing plasma viscosity. It is widely performed in the management of chronic diseases as a first-line or second-line therapy, or as a supportive treatment. During plasma exchange, a substantial portion of plasma containing toxins and other abnormal matter is extracted from the other blood components and replaced with replacement fluid, such as fresh frozen plasma (FFP) or albumin.

Key Market Drivers

High prevalence of Neurological, Renal, And Hematological Disorders

The high prevalence of chronic diseases, such as nephrological disorders, acute liver failure, Guillain-Barré Syndrome (GBS), and others, contributes to the growth of the overall therapeutic plasma exchange market. Additionally, there has been a surge in the application of therapeutic plasma exchange, accompanied by intensive research and clinical trials to assess its efficacy compared to other treatments. These factors significantly bolster the growth of the therapeutic plasma exchange market.

The most common indications for TPE therapy are nephrology-related disorders, as well as its use in the treatment of myasthenia gravis, Guillain Barré syndrome (GBS), and chronic inflammatory demyelinating polyneuropathy. Currently, the trend in therapeutic plasma exchange involves the use of highly permeable filters and standard dialysis equipment, often referred to as membrane plasma separation (MPS). In the US, the "Plasmaflo" membrane from Asahi Medical (Asahi Kasei Kuraray Medical Co., Ltd, Japan) is widely used.

Key Market Challenges

Risk Associated with Plasmapheresis Procedures

During the plasmapheresis procedure, a portion of blood is extracted from the human body, and specific replacement fluids like albumin, fresh frozen plasma (FFP), electrolyte solutions, purified protein products, and starches are administered intravenously to maintain intravascular osmotic pressure. Although generally considered safe, there are still several associated risks. Risk factors include infection, allergic reactions, hypotension, internal bleeding, electrolyte imbalance, and others. One of the most frequent side effects of plasmapheresis is hypotension, characterized by symptoms such as faintness, blurred vision, dizziness, sweating, or abdominal cramps. However, prompt treatment can effectively manage these symptoms.

Some patients may experience numbness or tingling around the mouth or nose due to the effect of the anticoagulant citrate on calcium levels in the body. In rare cases, bleeding may occur during the procedure as a result of anticoagulants added to the blood, potentially leading to irregular heartbeat and cardiac arrest if not promptly addressed. Allergic reactions, itching, and rash may also occur as a response to the replacement fluids, but these can be easily treated with intravenous medication. These side effects may impede the widespread adoption of plasmapheresis, thereby limiting market growth to some extent.

Key Market Trends

Continuous Advancement

Continuous technological advancements have significantly enhanced and refined high-precision methods. These advancements not only improve patient satisfaction but also enhance the processing of goods derived from blood and plasma. In comparison to other techniques such as membrane separation methods, this method requires minimal blood flow, making it a more advanced approach for facilitating blood collection through the patient's antecubital or radial veins. Moreover, these technological advancements allow for more precise control of hydration status, resulting in greater hemodynamic stability during treatment. Additionally, patients benefit from improved comfort and safety during therapeutic plasma exchange (TPE) procedures. These remarkable technological developments create lucrative opportunities within the market.

Key Market Players

Asahi Kasei Corporation
Baxter International Inc
B. Braun Melsungen AG
Cerus Corporation
Fresenius Kabi AG
Haemonetics Corporation
Hemacare Corporation
IncMedica S.p.A.
Kawasumi Laboratories
Terumo Corporation

Report Scope:

In this report, the Global Therapeutic Plasma Exchange Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Therapeutic Plasma Exchange Market, By Product:

Consumables
Devices

Therapeutic Plasma Exchange Market, By Technology:

Centrifugation
Membrane Separation

Therapeutic Plasma Exchange Market, By Indication:

Neurological Disorders
Haematology Disorders
Renal Disorders
Metabolic Disorders
Others

Therapeutic Plasma Exchange Market, By End User:

Blood Collection Centres & Blood Component Providers
Hospitals & Clinics
Blood Transfusion Centres
Others

Therapeutic Plasma Exchange Market, By Region:

North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Therapeutic Plasma Exchange Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

Detailed analysis and profiling of additional market players (up to five).

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Therapeutic Plasma Exchange Market Outlook

5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Consumables, Devices)
5.2.2. By Technology (Centrifugation, Membrane Separation)
5.2.3. By Indication (Neurological Disorders, Hematology Disorders, Renal Disorders, Metabolic Disorders, Others)
5.2.4. By End User (Blood Collection Centers & Blood Component Providers, Hospitals & Clinics, Blood Transfusion Centers, Others)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map

6. North America Therapeutic Plasma Exchange Market Outlook

6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Technology
6.2.3. By Indication
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Therapeutic Plasma Exchange Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Technology
6.3.1.2.3. By Indication
6.3.1.2.4. By End User
6.3.2. Canada Therapeutic Plasma Exchange Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Technology
6.3.2.2.3. By Indication
6.3.2.2.4. By End User
6.3.3. Mexico Therapeutic Plasma Exchange Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Technology
6.3.3.2.3. By Indication
6.3.3.2.4. By End User

7. Europe Therapeutic Plasma Exchange Market Outlook

7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Technology
7.2.3. By Indication
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Therapeutic Plasma Exchange Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Technology
7.3.1.2.3. By Indication
7.3.1.2.4. By End User
7.3.2. United Kingdom Therapeutic Plasma Exchange Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Technology
7.3.2.2.3. By Indication
7.3.2.2.4. By End User
7.3.3. Italy Therapeutic Plasma Exchange Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Technology
7.3.3.2.3. By Indication
7.3.3.2.4. By End User
7.3.4. France Therapeutic Plasma Exchange Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Technology
7.3.4.2.3. By Indication
7.3.4.2.4. By End User
7.3.5. Spain Therapeutic Plasma Exchange Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Technology
7.3.5.2.3. By Indication
7.3.5.2.4. By End User

8. Asia-Pacific Therapeutic Plasma Exchange Market Outlook

8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Technology
8.2.3. By Indication
8.2.4. By End User
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Therapeutic Plasma Exchange Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Technology
8.3.1.2.3. By Indication
8.3.1.2.4. By End User
8.3.2. India Therapeutic Plasma Exchange Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Technology
8.3.2.2.3. By Indication
8.3.2.2.4. By End User
8.3.3. Japan Therapeutic Plasma Exchange Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Technology
8.3.3.2.3. By Indication
8.3.3.2.4. By End User
8.3.4. South Korea Therapeutic Plasma Exchange Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Technology
8.3.4.2.3. By Indication
8.3.4.2.4. By End User
8.3.5. Australia Therapeutic Plasma Exchange Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Technology
8.3.5.2.3. By Indication
8.3.5.2.4. By End User

9. South America Therapeutic Plasma Exchange Market Outlook

9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Technology
9.2.3. By Indication
9.2.4. By End User
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Therapeutic Plasma Exchange Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Technology
9.3.1.2.3. By Indication
9.3.1.2.4. By End User
9.3.2. Argentina Therapeutic Plasma Exchange Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Technology
9.3.2.2.3. By Indication
9.3.2.2.4. By End User
9.3.3. Colombia Therapeutic Plasma Exchange Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Technology
9.3.3.2.3. By Indication
9.3.3.2.4. By End User

10. Middle East and Africa Therapeutic Plasma Exchange Market Outlook

10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Technology
10.2.3. By Indication
10.2.4. By End User
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Therapeutic Plasma Exchange Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Technology
10.3.1.2.3. By Indication
10.3.1.2.4. By End User
10.3.2. Saudi Arabia Therapeutic Plasma Exchange Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Technology
10.3.2.2.3. By Indication
10.3.2.2.4. By End User
10.3.3. UAE Therapeutic Plasma Exchange Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.2. By Technology
10.3.3.2.3. By Indication
10.3.3.2.4. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches

13. Global Therapeutic Plasma Exchange Market: SWOT Analysis

14. Porter’s Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Asahi Kasei Corporation
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (As Reported)
15.1.5. Recent Developments
15.1.6. Key Personnel Details
15.1.7. SWOT Analysis
15.2. Baxter International Inc
15.3. B. Braun Melsungen AG
15.4. Cerus Corporation
15.5. Fresenius Kabi AG
15.6. Haemonetics Corporation
15.7. Hemacare Corporation
15.8. IncMedica S.p.A.
15.9. Kawasumi Laboratories
15.10. Terumo Corporation

16. Strategic Recommendations17. About the Publisher & Disclaimer

Companies Mentioned

Asahi Kasei Corporation
Baxter International Inc
B. Braun Melsungen AG
Cerus Corporation
Fresenius Kabi AG
Haemonetics Corporation
Hemacare Corporation
IncMedica S.p.A.
Kawasumi Laboratories
Terumo Corporation

Table Information

Report Attribute	Details
No. of Pages	180
Published	August 2025
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 1.64 Billion
Forecasted Market Value ( USD ) by 2030	$ 2.57 Billion
Compound Annual Growth Rate	7.7%
Regions Covered	Global
No. of Companies Mentioned	10

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4006EUR$4,500USD£3,462GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€4897EUR$5,500USD£4,232GBP